Compare · NVO vs SKYE
NVO vs SKYE
Side-by-side comparison of Novo Nordisk A/S (NVO) and Skye Bioscience Inc. (SKYE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and SKYE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $206.96B, about 20867.3x SKYE ($9.9M).
- Over the past year, NVO is down 17.0% and SKYE is down 92.2% - NVO leads by 75.2 points.
- SKYE has been more active in the news (11 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 8 for SKYE).
- Company
- Novo Nordisk A/S
- Skye Bioscience Inc.
- Price
- $46.73+1.19%
- $0.27-2.53%
- Market cap
- $206.96B
- $9.9M
- 1M return
- -3.03%
- -57.88%
- 1Y return
- -17.03%
- -92.22%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 11
- Recent ratings
- 25
- 8
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest SKYE
- Director Schwab Andrew J. sold $140,313 worth of shares (375,840 units at $0.37) (SEC Form 4)
- Large owner 5am Partners Vii, Llc sold $140,313 worth of shares (375,840 units at $0.37) (SEC Form 4)
- SEC Form DEFA14A filed by Skye Bioscience Inc.
- Amendment: Skye Bioscience Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders
- SEC Form DEFA14A filed by Skye Bioscience Inc.
- SEC Form 8-K filed by Skye Bioscience Inc.
- SEC Form DEFA14A filed by Skye Bioscience Inc.
- SEC Form 10-Q filed by Skye Bioscience Inc.
- Skye Bioscience Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- Skye Bioscience and Redx Pharma Announce Transaction Agreement and $125 Million in Financings